ClinicalTrials.gg

Program

TQB2916

A development code. Also written as “TQB2916 Injection”, “TQB2916 injection + doxorubicin hydrochloride for injection” and “TQB2916 injection+penpulimab injection”.

In Sino Biopharmaceutical's pipeline, CD40激动型单抗. Its studies are mostly in Pancreatic Neoplasms · Sarcoma, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jul 8, 20243 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical32 open or runningphase 2since Jul 8, 2024Jan 26, 2022Aug 2027phase 2 · NCT06962267
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2916, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 26, 2022First study: phase 1 study in Advanced TumorsFirst studyNCT05213767 · 190 enrolled · China
  2. Jul 8, 2024Phase 2 study in SarcomaNCT06500091 · 54 planned · China
  3. Apr 30, 2025Phase 2 study in Pancreatic NeoplasmsNCT06962267 · 50 planned · China

Ahead

  1. Aug 2027Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06962267

TargetBeta

“CD40激动型单抗”the company's pipeline, read by Claude · source

Other programs on CD40

ProgramCompanyFurthest phaseStudies
Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324ruleMerck KGaA, Darmstadt, Germanyphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06962267Pancreatic Neoplasms · China2RecruitingAug 202750
NCT06500091Sarcoma · China2Not yet recruitingJun 202654
NCT05213767Advanced Tumors · China1UNKNOWNMay 2023190

How it is read

Names in the registry

  • “TQB2916 Injection”, 1 entry
  • “TQB2916 injection + doxorubicin hydrochloride for injection”, 1 entry
  • “TQB2916 injection+penpulimab injection”, 1 entry
  • “TQB2916 injection”, 1 entry

Codes read as this program: TQB2916.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.